SOUTH SAN FRANCISCO, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Anesiva, Inc. will announce financial results for the third quarter 2006 after the markets close on Thursday, November 9, 2006 and will hold a webcast teleconference at 4:30 p.m. EST that day. Members of Anesiva’s management team will discuss financial results from the third quarter and nine months ended September 30, 2006, as well as provide an overview of the company’s product pipeline, recent events and milestones.
Interested parties can listen to the live audio webcast by dialing 800-340-6289 (international dial: 706-634-1538) or by logging on to www.anesiva.com and going to the Investor Information page. Please connect to Anesiva’s website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 1251423. The webcast will be available until the company’s next quarterly financial results conference call.
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has three drug candidates in development for multiple pain-related indications, the most advanced of which, Zingo(TM), has completed Phase 3 clinical trials. The second product in the pipeline, 4975, has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. A third product, 1207, is currently being evaluated in a Phase 1 clinical trial as a topical local anesthetic. Anesiva is based in South San Francisco, CA. For more information about Anesiva’s leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to www.anesiva.com .
Anesiva, Inc.
CONTACT: Jennifer Cook Williams, Vice President, Investor Relations, ofAnesiva, Inc., +1-650-624-9600, or investors@anesiva.com
Web site: http://www.anesiva.com/
